Alnylam Pharmaceuticals
ALNY
#663
Rank
HK$236.42 B
Marketcap
HK$1,833
Share price
-8.67%
Change (1 day)
37.26%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -HK$1.46 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are HK$2.09 Billion. In 2023 the company made an earning of -HK$2.44 Billion, an increase over its 2022 earnings that were of -HK$7.56 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -HK$1.46 Billion-40.03%
2023 -HK$2.44 Billion-67.84%
2022 -HK$7.56 Billion36.93%
2021 -HK$5.52 Billion-8.04%
2020 -HK$6.01 Billion-15.66%
2019 -HK$7.12 Billion12.23%
2018 -HK$6.34 Billion62.91%
2017 -HK$3.9 Billion17.78%
2016 -HK$3.31 Billion43.44%
2015 -HK$2.31 Billion60.69%
2014 -HK$1.44 Billion98.2%
2013 -HK$0.73 Billion
2011 -HK$0.43 Billion27.48%
2010 -HK$0.34 Billion-10.92%
2009 -HK$0.38 Billion95.77%
2008 -HK$0.2 Billion
2006 -HK$0.31 Billion-9.13%
2005 -HK$0.34 Billion34.74%
2004 -HK$0.26 Billion36.79%
2003 -HK$0.19 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-HK$4.1 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$38.66 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.48 B-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$1.91 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.28 Billion-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$99.07 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$57.64 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
HK$6.43 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel